Anti-inflammatory agent 107

Anti-inflammatory agent 107 is an orally active anti-inflammatory agent. Anti-inflammatory agent 107 inhibits and NF-κB with a superior binding affinity of -9.4578 kcal/mol. Anti-inflammatory agent 107 reduces levels of inflammatory biomarkers (TNF-α, IL-6, INF-γ, NF-κβ, C-reactive protein and Erythrocyte Sedimentation Rate) and enhances the endogenous antioxidant defense system by elevating SOD (Superoxide Dismutase), CAT (Catalase) and GSH (Glutathione) activities. Anti-inflammatory agent 107 not induces liver toxicity and demonstrates hepatoprotective effects. Anti-inflammatory agent 107 dose-dependently ameliorates leukocyte infiltration and tissue edema. Anti-inflammatory agent 107 can be used for anti-inflammatory research[1].

Product Specifications

UNSPSC

12352005

Target

Glutathione Peroxidase; Interleukin Related; mTOR; NF-κB; SOD; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

CCOC(C1=C(OC2=C(C1C3=CC=CO3)C(C4=CC=CS4)=NN2C5=CC=C(C=C5[N+]([O-])=O)[N+]([O-])=O)NC(C6=CN=CC=C6)=O)=O

Molecular Formula

C29H20N6O9S

Molecular Weight

628.57

References & Citations

[1]Rizk HF, et al. Newly synthesized pyranopyrazole nicotinamides derivatives as potent anti-inflammatory agents: In-silico, in-vitro, and in-vivo studies. Bioorg Chem. 2025 Dec;167:109205.